Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2016

01-01-2016 | Original Article

Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

Authors: Xiaoqing Zhang, Junwei Fan, Yuping Li, Shengtao Lin, Ping Shu, Jian Ni, Shengying Qin, Zhemin Zhang

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

This study aimed to investigate the association of epidermal growth factor receptor (EGFR) gene polymorphism and AKT1 polymorphism with the clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (EGFR-TKIs). The clinical outcome and the survival of NSCLC of 230 patients after treatment with EGFR-TKIs were measured. The rs712829, rs1468727 of the EGFR gene and rs1130214 of the AKT1 gene from peripheral blood cell were detected by a multiplexed single nucleotide polymorphism (SNP) MassEXTEND assay. The relationship between genetic polymorphisms and clinical outcomes of treatment with EGFR-TKIs was analyzed. The response rates and the disease control rate of patients with genotype GG, GT, and TT in EGFR rs712829 were statistically very significant difference(19.7 vs 36.1 vs 50.0 %, P = 0.016 and 57.7 vs 77.8 vs 83.3 %, P = 0.026, respectively). Better disease control was also achieved in patients with the GG genotype of AKT1 rs1130214 than those with the GT and TT genotypes (65.6 vs. 48.7 %, P = 0.043). Patients carrying the EGFR rs712829 TT genotype had significantly longer PFS and OS than those with the GT or GG genotypes (9.0 vs. 7.0 vs. 5.0 months, P = 0.001 and 13.1 vs. 14.6 vs. 18.8 months, P = 0.008, respectively). In addition, patients carrying the AKT1 rs1130214 GG genotype also had significantly longer PFS than those with the GT and TT genotypes (5.5 vs. 4.5 months, P = 0.008). EGFR rs712829 polymorphism and AKT1 rs1130214 could influence the response to EGFR-TKIs therapy in patients with advanced NSCLC.
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
2.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
Bar J, Cyjon A, Flex D, Sorotsky H, Biran H, Dudnik J, et al. EGFR mutation testing practice in advanced non-small cell lung cancer. Lung. 2014;192:759–63.CrossRefPubMed
4.
Fumarola C, Bonelli MA, Petronini PG, Alfieri RR. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem Pharmacol. 2014;90:197–207.CrossRefPubMed
5.
Pallis AG, Syrigos KN. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC. Lung Cancer. 2013;80:120–30.CrossRefPubMed
6.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus standard Chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;3:239–46.
7.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C, et al. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol. 2012;3:300–8.CrossRef
8.
Shi Y, Zhang L, Liu X, Zhou C, Zhang L, Zhang S, et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013;14:953–61.CrossRefPubMed
9.
Kim GW, Song JS, Choi CM, Rho JK, Kim SY, Jang SJ, et al. Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival. Lung Cancer. 2015;88:139–46.CrossRefPubMed
10.
West HL, Franklin WA, McCoy J, Gumerlock PH, Vance R, Lau DH, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. J Clin Oncol. 2006;24:1807–13.CrossRefPubMed
11.
Yang CH, Yu CJ, Shih JY, Chang YC, Hu FC, Tsai MC, et al. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol. 2008;26:2745–53.CrossRefPubMed
12.
Zhang L, Yuan X, Chen Y, Du XJ, Yu S, Yang M. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib. Gene. 2013;517:60–4.CrossRefPubMed
13.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung ancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;53:133–44.CrossRef
14.
Liu W, He L, Ramírez J, Krishnaswamy S, Kanteti R, Wang YC, et al. Functional EGFR germline polymorphisms may confer risk for EGFR somatic mutations in non-small cell lung cancer, with a predominant effect on exon 19 microdeletions. Cancer Res. 2011;71:2423–7.CrossRefPubMedPubMedCentral
15.
Sasaki H, Okuda K, Shimizu S, Takada M, Kawahara M, Kitahara N, et al. EGFR R497K polymorphism is a favorable prognostic factor for advanced lung cancer. J Cancer Res Clin Oncol. 2009;35:313–8.CrossRef
16.
Wang F, Fu S, Shao Q, Zhou YB, Zhang X, Zhang X, et al. High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR. J Transl Med. 2013;11:90.CrossRefPubMedPubMedCentral
17.
Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28:744–52.CrossRefPubMed
18.
Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated nonsmall-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–18.CrossRefPubMed
19.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefPubMed
20.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.CrossRefPubMed
21.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.CrossRefPubMed
22.
Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Chen YM, et al. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis. 2013;34:612–9.CrossRefPubMed
23.
Liu W, Wu X, Zhang W, Montenegro RC, Fackenthal DL, Spitz JA, et al. Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res. 2007;13:6788–95.CrossRefPubMed
24.
Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, et al. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012;3:1128–35.CrossRef
25.
Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, et al. Prospective molecular marker analyses of EGFR and K S from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2011;9:4113–20.CrossRef
26.
Hou WG, Ai WB, Bai XG, Dong HL, Li Z, Zhang YQ, et al. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One. 2012;7:e37531.CrossRefPubMedPubMedCentral
27.
Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, et al. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase. PLoS One. 2012;7:e30427.CrossRefPubMedPubMedCentral
28.
Kim MJ, Kang HG, Lee SY, Jeon HS, Lee WK, Park JY, et al. AKT1 polymorphisms and survival of early stage non-small cell lung cancer. J Surg Oncol. 2012;105:167–74.CrossRefPubMed
29.
Remon J, Morán T, Majem M, Reguart N, Dalmau E, Márquez-Medina D, et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev. 2014;40:93–101.CrossRefPubMed
30.
Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom Mass ARRAY iPLEX platform. Current Protocols in Human Genetics 2009. Chapter 2, Unit 2 12.
31.
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007;39:347–51.CrossRefPubMed
32.
Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011;13:74–84.CrossRefPubMedPubMedCentral
33.
Remon J, Morán T, Reguart N, Majem M, Carcereny E, Lianes P. Beyond EGFR TKI in EGFR-mutant non-small cell lung cancer patients: main challenges still to be overcome. Cancer Treat Rev. 2014;40:723–9.CrossRefPubMed
34.
Shitara M, Sasaki H, Yokota K, Okuda K, Hikosaka Y, Moriyama S, et al. Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients. Exp Ther Med. 2012;4:785–9.PubMedPubMedCentral
35.
Giovannetti E, Zucali PA, Peters GJ, Cortesi F, D'Incecco A, Smit EF, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther. 2010;9:581–93.CrossRefPubMed
36.
Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, et al. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac Oncol. 2012;7:316–22.CrossRefPubMed
37.
38.
Fortier AM, Asselin E, Cadrin M. Functional specificity of Akt isoforms in cancer progression. Biomol Concepts. 2011;2:1–11.CrossRefPubMed
39.
Kumar A, Rajendran V, Sethumadhavan R, Purohit R. AKT kinase pathway: a leading target in cancer research. Sci World J. 2013;2013:756134.
40.
Giovannetti E, Erdem L, Olcay E, Leon LG, Peters GJ. Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer. Front Biosci (Landmark Ed). 2011;16:116–30.CrossRef
41.
Erdem L, Giovannetti E, Leon LG, Honeywell R, Peters GJ. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib. Curr Top Med Chem. 2012;12:1649–59.CrossRefPubMed
42.
Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, et al. PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer. 2011;71:82–8.CrossRefPubMed
43.
Xu MQ, Xing QH, Zheng YL, Li S, Gao JJ, He G, et al. Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. J Clin Psychiatry. 2007;68:1358–67.CrossRefPubMed
44.
Li W, Ren S, Li J, Li A, Fan L, Li X, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer. 2014;84:295–300.CrossRefPubMed
45.
Wang Y, Lin L, Xu H, Li T, Zhou Y, Dan H, et al. Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population. J Oral Pathol Med. 2015;44:45–50.CrossRefPubMed
46.
Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One. 2014;9(2):e85245.CrossRefPubMedPubMedCentral
Metadata
Title
Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Authors
Xiaoqing Zhang
Junwei Fan
Yuping Li
Shengtao Lin
Ping Shu
Jian Ni
Shengying Qin
Zhemin Zhang
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3893-1

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue

Original Article

The adaptor protein CrkII regulates IGF-1-induced biological behaviors of pancreatic ductal adenocarcinoma

Original Article

Prognostic analysis of primary mucin-producing adenocarcinoma of the lung: a comprehensive retrospective study

Original Article

PAQR3 plays a suppressive role in laryngeal squamous cell carcinoma

Original Article

Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance

Original Article

A comprehensive analysis of CDC20 overexpression in common malignant tumors from multiple organs: its correlation with tumor grade and stage

Review

Hsp90 regulates autophagy and plays a role in cancer therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits